Sua seleção (0)
Detalhe da pesquisa
1.
Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.
Hum Mol Genet;
26(21): 4301-4313, 2017 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28973304
2.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Lancet;
2018 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360969
3.
All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013).
Ann Rheum Dis;
78(6): 802-806, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30992296
4.
Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.
Ann Rheum Dis;
78(6): 796-801, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30910989
5.
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.
Ann Rheum Dis;
78(9): 1151-1159, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383717
6.
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
J Autoimmun;
: 102340, 2019 Oct 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31629628
7.
Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?
Rheumatology (Oxford);
2019 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593590
8.
The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis.
Rheumatology (Oxford);
2019 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31199486
9.
Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE.
Rheumatology (Oxford);
2019 Jun 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31236574
10.
Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen.
Rheumatology (Oxford);
58(7): 1259-1267, 2019 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753683
11.
Prologue: 2018 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
J Rheumatol Suppl;
95: 1-3, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31154397
12.
Best-practice Indicators in Psoriatic Disease Care.
J Rheumatol Suppl;
95: 38-45, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31154403
13.
GRAPPA 2018 Project Report.
J Rheumatol Suppl;
95: 54-57, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31154406
14.
Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting.
J Rheumatol Suppl;
95: 11-19, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31154399
15.
The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.
J Rheumatol Suppl;
95: 33-37, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31154402
16.
Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.
Am J Hum Genet;
97(6): 816-36, 2015 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26626624
17.
Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis.
Ann Rheum Dis;
77(11): 1573-1577, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30077991
18.
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
Ann Rheum Dis;
77(1): 3-17, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28684559
19.
A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.
Rheumatology (Oxford);
57(8): 1370-1376, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29688532
20.
Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).
Rheumatology (Oxford);
57(10): 1777-1788, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29945203